- Home
- SAMO vs AKBA Comparison
SAMO vs AKBA Comparison
Compare SAMO & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAMO | AKBA |
|---|---|---|
| Founded | 2026 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.8M | 248.3M |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SAMO | AKBA |
|---|---|---|
| Price | $9.80 | $0.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 109.4K | ★ 8.9M |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.79 | $0.36 |
| 52 Week High | $9.85 | $1.84 |
Technical Indicators
Market Signals| Indicator | SAMO | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 36.35 |
| Support Level | N/A | $0.36 |
| Resistance Level | $9.83 | $1.54 |
| Average True Range (ATR) | 0.01 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 25.00 | 24.73 |
Price Performance
Historical ComparisonAbout SAMO Samos Energy Acquisition Corporation Class A Ordinary Shares
Samos Energy Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.